Responsraterne (defineret ud fra en 30% - mindskning i CDRS- R- scoren) viste en statistisk signifikant forskel i det ene af de to centrale forsøg (58% for fluoxetin mod 32% for placebo, P=0, 013 og 65% for fluoxetin mod 54% for placebo, P=0, 093).
Response rates (the primary endpoint, defined as a 30% decrease in the CDRS-R score) demonstrated a statistically significant difference in one of the two pivotal studies (58% for fluoxetine versus 32% for placebo, P=0.013 and 65% for fluoxetine versus 54% for placebo, P=0.093).